Friday 6 November 2026 Export PEN’s income statement to Excel — free account

Penumbra, Inc.

PEN Healthcare Medical Devices

Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.

Revenue: +15.6%
EPS: −8.29%
Free cash flow: −37.2%
Total debt: −10.3%

Quarter to September 2026, against a year earlier

319.79 1.32 −0.41%

Follow PEN

Alert me

Market cap: $12.7B
P/E: 80.3×
Fwd P/E: 68.7×
Dividend yield: —
F-score: 8/9
Altman Z: 20.17
Beneish M: −2.48
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Penumbra, Inc. (PEN) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Penumbra, Inc. (PEN) trades at a price to free cash flow of 63.1×. Over the past ten years it has ranged from 0.0× (June 2023) to 26,154× (March 2018); the current reading is higher than 61% of that period. That is above the Medical Devices industry median of 28.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/PEN/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Penumbra, Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/PEN/metrics/price-to-free-cash-flow">Penumbra, Inc. (PEN) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	69.2×	11.05%
FY2024	62.3×	(46.24%)
FY2023	116×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	1,257×	478.47%
FY2018	217×	(98.84%)
FY2017	18,739×	—
FY2016	0.0×	—

Period	Price to free cash flow	Change
Sep 2026	62.6×	8.81%
Jun 2026	57.6×	(5.07%)
Mar 2026	60.6×	(12.35%)
Dec 2025	69.2×	6.64%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 26,154×

Ten-year median 0.0×

Current reading's percentile 61

Company	Price to free cash flow
SNN Smith & Nephew SNATS, Inc. compare	7.1×
GMED Globus Medical, Inc. compare	14.5×
BIO Bio-Rad Laboratories, Inc. compare	30.0×
BIO.B Bio-Rad Laboratories, Inc. compare	30.7×
BRKR Bruker Corporation compare	32.9×
PODD Insulet Corporation compare	46.4×
PEN Penumbra, Inc.	63.1×
TXG 10x Genomics compare	63.3×
GKOS Glaukos Corporation compare	360×
Medical Devices industry median	28.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Penumbra, Inc. (PEN) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on PEN

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on PEN

Stockrow Weekly